Product Information
SKYRIZI 360 MG/2.4 ML ON-BODY is a brand product labeled by AbbVie Inc., priced at $9572.6650 per ML under NDC 00074107001. Its NADAC has been published 111 times since Aug 21, 2024.
Manufacturer
AbbVie Inc.NDC
00074107001
Classification
Brand
Dosage Form
KIT
Route
INTRAVENOUS
Effective Date
9/23/2026
Approval Type
Biologic (BLA)
FDA Application
BLA761105On Market Since
6/16/2022
Price Statistics
The NADAC for SKYRIZI 360 MG/2.4 ML ON-BODY has been published 111 times since Aug 21, 2024, and over the history we have for it it has risen 12.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $9572.6650 per ML |
|---|---|
| All-time high | $9679.4921 (Jul 15, 2026) |
| All-time low | $8515.5350 (Aug 21, 2024) |
| 52-week high | $9679.4921 |
| 52-week low | $9069.0448 |
| Median price | $9069.0448 |
| Average price | $9166.8243 |
| Largest weekly change | +6.5% (Jan 8, 2025) |
| Weeks tracked | 111 |
| Tracking since | Aug 21, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Risankizumab-rzaa market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
AbbVie Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Risankizumab-rzaa market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SKYRIZI 360 MG/2.4 ML ON-BODY?
The current National Average Drug Acquisition Cost (NADAC) for SKYRIZI 360 MG/2.4 ML ON-BODY, manufactured by AbbVie Inc., is $9572.6650 per ML (NDC 00074107001), effective Sep 30, 2026.
How has the price of SKYRIZI 360 MG/2.4 ML ON-BODY changed over time?
Over the history we have for it, the NADAC for SKYRIZI 360 MG/2.4 ML ON-BODY has risen 12.4%. It has been tracked across 111 weekly CMS publications since Aug 21, 2024.
What are the highest and lowest recorded NADAC prices for SKYRIZI 360 MG/2.4 ML ON-BODY?
Since Aug 21, 2024, the NADAC for SKYRIZI 360 MG/2.4 ML ON-BODY has ranged from a low of $8515.5350 (Aug 21, 2024) to a high of $9679.4921 (Jul 15, 2026), with a median of $9069.0448 per ML.
Are there cheaper alternatives to SKYRIZI 360 MG/2.4 ML ON-BODY?
No other NADAC-published product currently shares the active ingredient and strength of SKYRIZI 360 MG/2.4 ML ON-BODY in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures SKYRIZI 360 MG/2.4 ML ON-BODY?
SKYRIZI 360 MG/2.4 ML ON-BODY (NDC 00074107001) is labeled by AbbVie Inc., and CMS classifies it as a brand product.